CHITOSAN ADDUCT WITH TRANEXAMIC ACID AND ITS HAEMOSTATIC EFFECT

• Autorzy: ,,,, , Nazar Manko , Lidiia Panchak , Semen Khomyak , Rostyslav Stoika
• Języki publikacji: EN

Abstrakty

EN

Chitosan is a cationic polymer capable of binding acidic drugs. In addition, it has haemostatic and antimicrobial activity. Chitosan derivatives withanti-fibrinolytic properties may present increased effectiveness, especially when the added substance forms an adduct with chitosan. The aim of this work was to study the haemostatic action of the chitosan–tranexamic acid complex. Two chitosan solutions (molecularweight of 250 and 625 kDa at pH 5.7 and 6.2, and after tranexamic acid had been added to chitosan solutions) werestudied. Haemostatic evaluation was performed on white outbred mice. The time to complete cessation of bleeding from the tail was determined. Chitosan 625 kDa at pH 6.2 had the best haemostatic properties. Adding tranexamic acid to the chitosan solution reduced the bleeding time. This phenomenon was more pronounced for chitosan 625 kDa. Compared with control animals, this chitosan reduced bleeding arrest time by 30% and the chitosan–tranexamic acid adduct reduced the bleeding arrest time by 75%.

Słowa kluczowe

EN

adduct; chitosan; tranexamic acid; haemostatic effect

• Czasopismo: Progress on Chemistry and Application of Chitin and its Derivatives
• Rocznik: 2022
• Tom: 27
• Strony: 35-42

Twórcy

autor

,,,,

• Danylo Halytsky Lviv National Medical University,

autor

Nazar Manko

• Institute of Cell Biology, NAS Ukraine

autor

Lidiia Panchak

• 1Danylo Halytsky Lviv National Medical University

autor

Semen Khomyak

• Lviv Polytechnic National University

autor

Rostyslav Stoika

• Ivan Franko National University of Lviv

Bibliografia

• [1] Cheung RCF, Bun Ng T,Wong JH, Chan WY; (2015) Chitosan: an update on potential biomedical and pharmaceutical applications. Marine Drugs 13, 5156-5186. DOI:10.3390/md13085156
• [2] Wang W, Meng Q, Li Q, Liu J, Zhou M, Jin Z, Zhao K; (2020)Chitosan derivatives and their application in biomedicine. Int J MolSci 21, 487.DOI:10.3390/ijms21020487
• [3] Antonyuk V, Manko N, NektegaevI, Stoika R; (2021) Pharmacokinetics of ethacridine conjugated with chitosan in rats.Methods Objects Chem Anal 16(1), 41-47 DOI:10.17721/moca.2021.41-47
• [4] Lootsik MD,Bilyy RO,Lutsyk MM, StoikaRS; (2015)Preparationof chitosan with high blood clotting activity and its hemostatic potential assessment.BiotechnolActa 8(6), 32-40. DOI:10.15407/biotech8.06.032
• [5] Kadyseva OV, BykovVN., Strelova OY, Grebenyuk AN; (2021) Study of the effect of the physicochemical properties of chitosan on its haemostatic activity. Progress ChemAppl Chitin Deriv26, 112-120. DOI:10.15259/PCACD.26.010
• [6] Singh R, Shitiz K, Singh A; (2017). Chitin and chitosan: biopolymers for wound management. IntWound J 14(6), 1276-1289. DOI:10.1111/iwj.12797
• [7] Pogorielov MV, Sikora VZ; (2015). Chitosan as a hemostatic agent: current state. Eur J Med B 2(1), 24-33.DOI:10.13187/ejm.s.b.2015.2.24
• [8] Klokkevold PR, Fukayama H, Sung EC, Bertolami CN; (1999). The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. J Oral Maxillofacial Surg57(1), 49-52. DOI:10.1016/S0278-2391(99)90632-8
• [9] Wang XH, Li DP, Wang WJ, Feng QL, Cui FZ, Xu YX, Song XH, van der Werf M; (2003) Crosslinkedcollagen/chitosan matrices for artificial livers. Biomaterials 24, 3213-3220. DOI:10.1016/S0142-9612(03)00170-4
• [10] McCormack PL; (2012) Tranexamicacid. A review of its use in the treatment of hyperfibrinolysis. Drugs 72, 585-617. DOI:10.2165/11209070-000000000-00000
• [11] Klauss M, Knorr J, Breuer T, Gertler R, MacGuil M, Lange R, Tassani P, Wiesner G; (2011) Seizures after open heart surgery: comparison of e-aminocaproic acid and tranexamic acid. J CardiothoracVascAnesth25(1), 20-25.DOI:10.1053/j.jvca.2010.10.007
• [12] Suresh MR, Valdez-Delgado KK, VanFosson CA, Trevino JD, Mann-Salinas EA, Shackelford SA, Staudt AM; (2020). Anatomic injury patterns in combat casualties treated by forward surgical teams. J Trauma Acute Care Surg89(2S), S231-S236. DOI:0.1097/TA.0000000000002720
• [13] Liu JL, Li JY, Jiang P, Jia W, Tian X, Cheng ZY, Zhang YX; (2020). Literature review of peripheral vascular trauma: is the era of intervention coming? Chin J Traumatol 23(1), 5-9. DOI:10.1016/j.cjtee.2019.11.003.
• [14] Hauschild VD, Schuh-Renner A, Lee T, RichardsonMD, Hauret K, Jones BH; (2019) Using causal energy categories to report the distribution of injuries in an active population: an approach used by the US Army. J Sci MedSport, 22(9), 997-1003. DOI:10.1016/j.jsams.2019.04.001
• [15] Okamoto Y, Yano R, Miyatake K, Tomohiro I, Shigemasa Y, Minami S; (2003) Effects of chitin and chitosan on blood coagulation. CarbohydrPolym 53, 337-342. DOI:10.1016/S0144-8617(03)00076-6
• [16] Boulton AJ, Lewis CT, Naumann DN, Midwinte MJ; (2018) Prehospital haemostatic dressings for trauma: a systematic review. Emerg Med J 35(7), 449-457. DOI:10.1136/emermed-2018-207523
• [17] Kang P-L, Chang SJ, Manousakas I, Lee CW, Yao C-H, Lin F-H, Kuo SM; (2011) Development and assessment of hemostasis chitosan dressings. CarbohydrPolym 85(3), 565-570. DOI:10.1016/j.carbpol.2011.03.015

• Typ dokumentu: article